Percutaneous radio frequency ablation of small renal tumors: initial results.

PubWeight™: 1.74‹?› | Rank: Top 3%

🔗 View Article (PMC 4136670)

Published in J Urol on January 01, 2002

Authors

Christian P Pavlovich1, McClellan M Walther, Peter L Choyke, Stephen E Pautler, Richard Chang, W Marston Linehan, Bradford J Wood

Author Affiliations

1: Urologic Oncology Branch, National Cancer Institute and Division of Radiology, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland.

Articles citing this

Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology (2005) 3.51

Feasibility and outcomes of repeat partial nephrectomy. J Urol (2008) 1.41

Percutaneous tumor ablation with radiofrequency. Cancer (2002) 1.31

Partial nephrectomy after previous radio frequency ablation: the National Cancer Institute experience. J Urol (2009) 1.21

Radiofrequency ablation beyond the liver. Tech Vasc Interv Radiol (2002) 1.19

Radio frequency ablation of small renal tumors:: intermediate results. J Urol (2004) 1.13

In vivo guidance and assessment of liver radio-frequency ablation with acoustic radiation force elastography. Ultrasound Med Biol (2008) 1.13

Biopsy of renal masses: when and why. Cancer Imaging (2009) 1.04

Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. J Urol (2010) 0.93

Image-guided radiofrequency ablation of renal cell carcinoma. Eur Radiol (2006) 0.90

Image guided tumour ablation. Cancer Imaging (2005) 0.89

Radiofrequency ablation of renal tumors. Eur Radiol (2004) 0.88

CT-guided radiofrequency ablation of pediatric Wilms tumor in a solitary kidney. Pediatr Radiol (2005) 0.88

Computed tomography and magnetic resonance imaging appearance of renal neoplasms after radiofrequency ablation and cryoablation. Semin Ultrasound CT MR (2009) 0.88

Image-guided radiofrequency ablation of Bosniak category III or IV cystic renal tumors: initial clinical experience. Eur Radiol (2008) 0.85

Percutaneous radiofrequency ablation of renal cell carcinoma. Eur Radiol (2005) 0.84

Review of the efficacy and safety of cryoablation for the treatment of small renal masses. Can Urol Assoc J (2013) 0.83

Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol (2004) 0.83

Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World J Urol (2012) 0.83

Radiofrequency ablation and cryoablation of renal tumours. Curr Oncol (2007) 0.83

Radiofrequency-assisted laparoscopic partial nephrectomy: clinical and histologic results. J Endourol (2007) 0.79

Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses. Can Urol Assoc J (2009) 0.78

Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma. J Kidney Cancer VHL (2015) 0.78

Percutaneous US-guided RF thermal ablation for malignant renal tumors: preliminary results in 13 patients. Eur Radiol (2004) 0.76

Advanced renal cell carcinoma associated with von Hippel-Lindau disease: A case report and review of the literature. Oncol Lett (2015) 0.75

Kidney cancer: Is incomplete renal ablation linked to tumour progression? Nat Rev Urol (2012) 0.75

Re: Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 0.75

Decision Making: Thermal Ablation Options for Small Renal Masses. Semin Intervent Radiol (2017) 0.75

Articles cited by this

Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg (2000) 3.97

Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer (2000) 2.59

Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg (1998) 2.19

Radio-frequency ablation of renal cell carcinoma: early clinical experience. Radiology (2000) 2.15

Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol (1999) 1.84

Radiofrequency ablation: a minimally invasive technique with multiple applications. Cancer J Sci Am (1999) 1.70

Percutaneous renal tumor cryoablation with magnetic resonance imaging guidance. J Urol (2001) 1.52

Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol (1999) 1.52

Ablation of renal tumors in a rabbit model with interstitial saline-augmented radiofrequency energy: preliminary report of a new technology. Urology (1999) 1.49

Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol (2001) 1.45

Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol (1997) 1.34

Radiofrequency ablation followed by resection of malignant liver tumors. Am J Surg (1999) 1.30

Radio frequency ablation of renal cell carcinoma via image guided needle electrodes. J Urol (1999) 1.29

The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol (1992) 1.27

The natural history of small renal masses. J Urol (2000) 1.19

Morphology of tissue destruction induced by focused ultrasound. Eur Urol (1993) 1.13

Observation of small incidentally detected renal masses. Semin Urol Oncol (1995) 1.05

Pseudotumors after renal parenchymal sparing surgery. J Urol (1998) 1.05

Laparoscopic renal cryoablation in 32 patients. Urology (2000) 1.04

Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol (1995) 0.96

A phase 2 study of radio frequency interstitial tissue ablation of localized renal tumors. J Urol (2000) 0.88

Renal cell carcinoma: the size variable. J Surg Oncol (1993) 0.86

Articles by these authors

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44

Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57

von Hippel-Lindau disease. Lancet (2003) 6.20

Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47

Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10

Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol (2011) 4.99

Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84

Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72

Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64

Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61

Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13

Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02

Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol (2011) 4.01

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88

Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75

Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51

The genetic basis of cancer of the kidney. J Urol (2003) 3.45

New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35

Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26

Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16

Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15

Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12

Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12

Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07

Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95

Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88

Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol (2013) 2.81

Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79

Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76

Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71

High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70

Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61

Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59

Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55

Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology (2003) 2.53

In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51

Initial experience with robotic-assisted laparoscopic radical prostatectomy in the Canadian health care system. Can Urol Assoc J (2007) 2.48

Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46

11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42

Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39

Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38

Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38

Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35

Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33

The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32

Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2009) 2.29

Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28

Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27

Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol (2009) 2.27

Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25

Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24

Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21

Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19

MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19

Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res (2007) 2.17

Genome-wide analysis of mouse transcripts using exon microarrays and factor graphs. Nat Genet (2005) 2.15

The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell (2011) 2.12

D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10

Effects of perfusion on radiofrequency ablation in swine kidneys. Radiology (2004) 2.07

UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet (2010) 2.06

High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab (2006) 2.04

In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res (2007) 2.01

Electromagnetic tracking for thermal ablation and biopsy guidance: clinical evaluation of spatial accuracy. J Vasc Interv Radiol (2007) 2.00

Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97

Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol (2013) 1.96

Closed-loop control in fused MR-TRUS image-guided prostate biopsy. Med Image Comput Comput Assist Interv (2007) 1.95

Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology (2009) 1.95

Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics (2004) 1.92